Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Sep 17, 2024 7:25pm

46 Views

Post# 36228166

RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

Excellent...
Will this be a similar to the seamless Phase II ---> Phase III that the Brad Thomson spoke about at the Richmond Club presentation in October 2016?

If I recall, ONCY had filed for a Phase II study of Pela in combination with FOLFOX-6 and Avastin in female patients with colorectal cancer, metatstatic to the liver.

This is the trial where he announced they would be 'hopefully' filing the Phase III study after the first patient had been treated, in Dec of 2016..

Is this going to be a similar set up... thanks for helping with your clear explanations. You rock.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide